News
PROF
9.29
-5.40%
-0.53
Benzinga's Top Ratings Upgrades, Downgrades For March 21, 2023
Benzinga · 03/21 15:00
Profound Medical cut to Hold at Jefferies on valuation
Seeking Alpha · 03/21 14:13
Jefferies Downgrades Profound Medical to Equal-Weight, Raises Price Target to $10
Benzinga · 03/21 09:38
Jefferies Downgrades Profound Medical to Hold From Buy, Adjusts Price Target to $10 From $5.50
Jefferies Downgrades Profound Medical to Hold From Buy, Adjusts Price Target to $10 From $5.50
MT Newswires · 03/21 07:58
Profound Medical Corp. 2022 Q4 - Results - Earnings Call Presentation
Seeking Alpha · 03/07 21:50
Profound Medical GAAP EPS of -$0.46 misses by $0.09, revenue of $1.3M misses by $1.39M
Seeking Alpha · 03/07 21:37
Profound Medical Q4 EPS $(0.46) Misses $(0.36) Estimate, Sales $1.30M Miss $2.72M Estimate
Benzinga · 03/07 21:10
Profound Medical Fourth-Quarter Loss Narrows as Sales Rise
Profound Medical Fourth-Quarter Loss Narrows as Sales Rise
MT Newswires · 03/07 16:19
Earnings Scheduled For March 7, 2023
Benzinga · 03/07 13:37
Morning News Call - Canada, March 7
Reuters · 03/07 13:10
Earnings Preview For Profound Medical
Benzinga · 03/06 16:01
Zoetis (ZTS) Matches Q4 Earnings Estimates
NASDAQ · 02/14 13:15
Veracyte: Building Momentum Around Decipher, Awaiting FY22 Numbers Before Entry
Seeking Alpha · 02/08 06:21
Profound Medical: Upsides Leading Into FY22 Earnings, Revise To Buy
Seeking Alpha · 02/04 11:13
Profound Medical to Present at the 2022 Jefferies London Healthcare Conference
TORONTO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased t...
GlobeNewswire · 11/08/2022 21:30
Profound Medical GAAP EPS of $0.24 beats by $0.61, revenue of $2.03M misses by $0.66M
Seekingalpha · 11/07/2022 22:06
Raymond James Upgrades Profound Medical to Strong Buy
Benzinga · 11/04/2022 18:55
BioAtla, TransMedics top healthcare gainers; Pulmonx, NeuroBo lead losers' pack
Seekingalpha · 11/04/2022 14:02
Profound Medical Announces Third Quarter 2022 Financial Results
TORONTO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased t...
GlobeNewswire · 11/03/2022 20:05
Profound Medical to Release Third Quarter 2022 Financial Results on November 3 – Conference Call to Follow
TORONTO, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased t...
GlobeNewswire · 10/13/2022 20:30
More
Webull provides a variety of real-time PROF stock news. You can receive the latest news about Profound Med Corp through multiple platforms. This information may help you make smarter investment decisions.
About PROF
Profound Medical Corp. is a Canada-based commercial-stage medical device company. The Company is focused on the development and marketing of customizable, incision-free therapeutic systems for the image-guided ablation of diseased tissue utilizing its platform technologies and leveraging the healthcare systems existing imaging infrastructure. The Company is commercializing TULSA-PRO, which is a technology that combines real-time magnetic resonance imaging (MRI), transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while actively protecting the urethra and rectum to help preserve the patient’s natural functional abilities. The Company is also commercializing Sonalleve, which is a therapeutic platform for the treatment of uterine fibroids and palliative pain treatment of bone metastases.